Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 24.9 Billion JPY | 167.64% |
| 2022 | -36.82 Billion JPY | -19.49% |
| 2021 | -30.81 Billion JPY | -31.78% |
| 2020 | -23.38 Billion JPY | -73.27% |
| 2019 | -13.49 Billion JPY | -14.41% |
| 2018 | -11.79 Billion JPY | 38.27% |
| 2017 | -19.1 Billion JPY | -173.01% |
| 2016 | -6.99 Billion JPY | -468.56% |
| 2015 | -1.23 Billion JPY | -108.61% |
| 2014 | 14.3 Billion JPY | 298.26% |
| 2013 | -7.21 Billion JPY | -184.33% |
| 2012 | -2.53 Billion JPY | -79.27% |
| 2011 | -1.41 Billion JPY | 19.18% |
| 2010 | -1.75 Billion JPY | 5.73% |
| 2009 | -1.85 Billion JPY | -5.06% |
| 2008 | -1.76 Billion JPY | 63.97% |
| 2007 | -4.9 Billion JPY | 45.19% |
| 2006 | -8.95 Billion JPY | -12.53% |
| 2005 | -7.95 Billion JPY | -89.59% |
| 2004 | -4.19 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 16.88 Billion JPY | -15.94% |
| 2024 Q2 | 20.09 Billion JPY | -22.6% |
| 2024 Q1 | 25.95 Billion JPY | 4.21% |
| 2023 Q3 | 30.92 Billion JPY | 187.98% |
| 2023 Q4 | 24.9 Billion JPY | -19.45% |
| 2023 FY | 24.9 Billion JPY | 167.64% |
| 2023 Q2 | -35.14 Billion JPY | 3.06% |
| 2023 Q1 | -36.25 Billion JPY | 1.53% |
| 2022 FY | -36.82 Billion JPY | -19.49% |
| 2022 Q4 | -36.82 Billion JPY | -16.88% |
| 2022 Q1 | -29.55 Billion JPY | 4.1% |
| 2022 Q2 | -24 Billion JPY | 18.78% |
| 2022 Q3 | -31.5 Billion JPY | -31.26% |
| 2021 FY | -30.81 Billion JPY | -31.78% |
| 2021 Q1 | -23.6 Billion JPY | -0.95% |
| 2021 Q2 | -23.8 Billion JPY | -0.86% |
| 2021 Q3 | -20.71 Billion JPY | 13.0% |
| 2021 Q4 | -30.81 Billion JPY | -48.77% |
| 2020 Q2 | -13.71 Billion JPY | 6.29% |
| 2020 Q1 | -14.63 Billion JPY | -8.4% |
| 2020 Q4 | -23.38 Billion JPY | -10.07% |
| 2020 FY | -23.38 Billion JPY | -73.27% |
| 2020 Q3 | -21.24 Billion JPY | -54.97% |
| 2019 Q3 | -14.34 Billion JPY | -47.26% |
| 2019 FY | -13.49 Billion JPY | -14.41% |
| 2019 Q2 | -9.74 Billion JPY | 7.08% |
| 2019 Q1 | -10.48 Billion JPY | 0.0% |
| 2019 Q4 | -13.49 Billion JPY | 5.94% |
| 2018 Q1 | -19.1 Billion JPY | 14.06% |
| 2018 Q3 | -13.57 Billion JPY | 18.23% |
| 2018 Q2 | -16.6 Billion JPY | 13.1% |
| 2018 FY | -11.79 Billion JPY | 38.27% |
| 2017 Q1 | -6.99 Billion JPY | 13.11% |
| 2017 FY | -19.1 Billion JPY | -173.01% |
| 2017 Q4 | -22.23 Billion JPY | -1150.45% |
| 2017 Q3 | -1.77 Billion JPY | -6.72% |
| 2017 Q2 | -1.66 Billion JPY | 76.2% |
| 2016 FY | -6.99 Billion JPY | -468.56% |
| 2016 Q4 | -8.05 Billion JPY | -3.14% |
| 2016 Q1 | -1.23 Billion JPY | 53.02% |
| 2016 Q3 | -7.81 Billion JPY | 36.48% |
| 2016 Q2 | -12.29 Billion JPY | -898.78% |
| 2015 Q2 | 13.06 Billion JPY | -8.68% |
| 2015 FY | -1.23 Billion JPY | -108.61% |
| 2015 Q3 | 4.27 Billion JPY | -67.26% |
| 2015 Q4 | -2.62 Billion JPY | -161.26% |
| 2015 Q1 | 14.3 Billion JPY | 282.21% |
| 2014 Q4 | -7.85 Billion JPY | -3.4% |
| 2014 Q3 | -7.59 Billion JPY | -2.65% |
| 2014 Q2 | -7.39 Billion JPY | -2.52% |
| 2014 Q1 | -7.21 Billion JPY | -119.09% |
| 2014 FY | 14.3 Billion JPY | 298.26% |
| 2013 FY | -7.21 Billion JPY | -184.33% |
| 2013 Q1 | -2.53 Billion JPY | -5.79% |
| 2013 Q2 | -2.27 Billion JPY | 10.41% |
| 2013 Q4 | -3.29 Billion JPY | -47.92% |
| 2013 Q3 | -2.22 Billion JPY | 2.07% |
| 2012 Q3 | -995.01 Million JPY | 11.6% |
| 2012 Q1 | -1.41 Billion JPY | 3.83% |
| 2012 FY | -2.53 Billion JPY | -79.27% |
| 2012 Q4 | -2.39 Billion JPY | -141.07% |
| 2012 Q2 | -1.12 Billion JPY | 20.48% |
| 2011 FY | -1.41 Billion JPY | 19.18% |
| 2011 Q4 | -1.47 Billion JPY | -23.76% |
| 2011 Q1 | -1.75 Billion JPY | 10.12% |
| 2011 Q3 | -1.18 Billion JPY | 17.72% |
| 2011 Q2 | -1.44 Billion JPY | 17.47% |
| 2010 FY | -1.75 Billion JPY | 5.73% |
| 2010 Q2 | -1.67 Billion JPY | 9.83% |
| 2010 Q3 | -2.15 Billion JPY | -28.35% |
| 2010 Q1 | -1.85 Billion JPY | 4.59% |
| 2010 Q4 | -1.94 Billion JPY | 9.38% |
| 2009 Q3 | -2.16 Billion JPY | 0.0% |
| 2009 Q4 | -1.94 Billion JPY | 9.95% |
| 2009 FY | -1.85 Billion JPY | -5.06% |
| 2009 Q1 | -1.76 Billion JPY | 25.71% |
| 2008 Q4 | -2.38 Billion JPY | 0.0% |
| 2008 FY | -1.76 Billion JPY | 63.97% |
| 2007 FY | -4.9 Billion JPY | 45.19% |
| 2006 FY | -8.95 Billion JPY | -12.53% |
| 2005 FY | -7.95 Billion JPY | -89.59% |
| 2004 FY | -4.19 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | -3253.443% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 2296.583% |
| GNI Group Ltd. | -17.93 Billion JPY | 238.89% |
| Linical Co., Ltd. | -4.46 Billion JPY | 658.064% |
| Trans Genic Inc. | -221.16 Million JPY | 11361.976% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 666.861% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 619.997% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | -1637.521% |
| AnGes, Inc. | -3.79 Billion JPY | 755.862% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | 6019.103% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | 5100.06% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | 5441.087% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 1020.429% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 1419.14% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 2636.089% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 833.231% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 2507.608% |
| Kidswell Bio Corporation | 343.58 Million JPY | -7149.359% |
| PeptiDream Inc. | 3.29 Billion JPY | -656.624% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 2660.989% |
| Ribomic Inc. | -2.09 Billion JPY | 1286.24% |
| SanBio Company Limited | -3.78 Billion JPY | 757.252% |
| Healios K.K. | -2.19 Billion JPY | 1237.352% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | 2736.158% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 1049.185% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 1857.721% |
| StemRIM | -8.41 Billion JPY | 396.171% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 631.827% |
| FunPep Company Limited | -1.79 Billion JPY | 1488.887% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 1265.837% |
| Stella Pharma Corporation | -1.11 Billion JPY | 2325.113% |
| TMS Co., Ltd. | -3.44 Billion JPY | 822.677% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 548.333% |
| Cuorips Inc. | -5.56 Billion JPY | 547.904% |
| K Pharma,Inc. | -3.26 Billion JPY | 862.55% |
| Takara Bio Inc. | -32.2 Billion JPY | 177.347% |
| ReproCELL Incorporated | -2.93 Billion JPY | 947.483% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | 3868.458% |
| StemCell Institute Inc. | -2.83 Billion JPY | 978.045% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 1305.414% |
| CellSeed Inc. | -2.01 Billion JPY | 1337.946% |